Arthralgia Market Report 2026

Arthralgia Market Overview

• Arthralgia market size has reached to $5.62 billion in 2025 • Expected to grow to $8.26 billion in 2030 at a compound annual growth rate (CAGR) of 7.9% • Growth Driver: Rising Rheumatoid Arthritis Cases Driving The Market Growth • Market Trend: RMAT Designation Granted For Gene Therapy In Osteoarthritis Treatment • North America was the largest region in 2025.

What Is Covered Under Arthralgia Market?

Arthralgia refers to pain in one or more joints, often without inflammation, and can result from various causes such as infections, autoimmune diseases, or injury. It is a symptom rather than a condition, typically indicating an underlying health issue affecting the joints. The main causes of arthralgia are osteoarthritis, rheumatoid arthritis, gout, psoriatic arthritis, lupus, injuries, infections, and other factors. Osteoarthritis is a degenerative joint disease that occurs when the protective cartilage that cushions the ends of the bones wears down over time. Various types of treatments are available, such as medications, therapies, surgical interventions, and lifestyle and home remedies. These treatments are administered through different routes, including oral, injectable, topical, and transdermal. They are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by several end users, including hospitals, clinics, home care settings, and rehabilitation centers.

What Is The Arthralgia Market Growth Forecast?

The arthralgia market size is expected to see strong growth in the next few years. It will grow to $8.26 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing demand for personalized treatment regimens, rising adoption of biologic and targeted therapies, expansion of home-based pain management solutions, growing focus on long-term symptom management, increasing investments in joint health research. Major trends in the forecast period include increasing adoption of personalized pain management therapies, rising use of combination treatment approaches, growing focus on early diagnosis of joint disorders, expansion of non-invasive pain relief solutions, enhanced patient-centered treatment models.

Global Arthralgia Market Segmentation

1) By Cause: Osteoarthritis, Rheumatoid Arthritis, Gout, Psoriatic Arthritis, Lupus, Injuries, Infections, Other Causes 2) By Treatment Type: Medications, Therapies, Surgical Interventions, Lifestyle And Home Remedies 3) By Route Of Administration: Oral, Injectable, Topical, Transdermal 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End User: Hospital, Clinics, Homecare Settings, Rehabilitation Centers Subsegments: 1) By Osteoarthritis: Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Spine Osteoarthritis, Shoulder Osteoarthritis 2) By Rheumatoid Arthritis: Seropositive Rheumatoid Arthritis, Seronegative Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Early-Onset Rheumatoid Arthritis 3) By Gout: Primary Gout, Secondary Gout, Gouty Arthritis 4) By Psoriatic Arthritis: Symmetric Psoriatic Arthritis, Asymmetric Psoriatic Arthritis, Psoriatic Spondylitis, Distal Interphalangeal Predominant Psoriatic Arthritis 5) By Lupus: Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus, Drug-induced Lupus, Neonatal Lupus 6) By Injuries: Sports-related Injuries, Trauma and Fractures, Sprains and Strains, Tendon or Ligament Damage 7) By Infections: Septic Arthritis, Viral Arthritis, Bacterial Infections, Fungal Infections 8) By Other Causes: Fibromyalgia, Overuse Injuries, Sarcoidosis, Ankylosing Spondylitis, Crystal-induced Arthritis

What Is The Driver Of The Arthralgia Market?

The increasing number of cases of rheumatoid arthritis is expected to propel the growth of the arthralgia market going forward. Rheumatoid arthritis is a chronic autoimmune disorder that primarily affects joints, causing inflammation, pain, and potential joint damage. The rising number of rheumatoid arthritis cases is attributed to aging populations, genetic predisposition, lifestyle changes, and environmental factors like smoking and pollution. Rheumatoid arthritis (RA) causes arthralgia by triggering chronic inflammation in the joints, leading to pain, stiffness, and progressive damage. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, by 2040, arthritis cases in Australia are expected to rise to 5.39 million from 4.11 million in 2025, with osteoarthritis increasing to 3.11 million from 2.35 million and rheumatoid arthritis reaching 748,721. Therefore, the increasing number of cases of rheumatoid arthritis is driving the growth of the arthralgia industry.

Key Players In The Global Arthralgia Market

Major companies operating in the arthralgia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., UCB S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals, KD Pharma Group S.A., SI-BONE Inc., Xalud Therapeutics Inc., Incannex Healthcare Limited, Cytonics Corporation

Global Arthralgia Market Trends and Insights

Major companies operating in the arthralgia market are focusing on developing innovative therapies, such as RMAT-designated gene therapy, to provide patients with advanced treatments that offer long-term pain relief and improved joint function. RMAT-designated gene therapy refers to a treatment that has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which expedites the development and review of innovative gene therapies for serious or life-threatening conditions. For instance, in March 2024, Pacira BioSciences Inc., a US-based pharmaceutical company, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation for its product PCRX-201 (enekinragene inzadenovec) by the U.S. Food and Drug Administration (FDA). It is an innovative, intra-articular gene therapy candidate utilizing a helper-dependent adenovirus (HDAd) to treat knee osteoarthritis. The therapy is designed to produce interleukin-1 receptor antagonists (IL-1Ra). Pacira expressed pride in receiving the FDA's first-ever RMAT designation for a gene therapy targeting osteoarthritis and emphasized the promising preliminary clinical results that suggest PCRX-201 may be a potential disease-modifying treatment.

What Are Latest Mergers And Acquisitions In The Arthralgia Market?

In November 2023, Nevro Corp., a US-based medical device company, acquired Vyrsa Technologies for $75 million. With this acquisition, Nevro aims to expand its chronic pain treatment portfolio by integrating Vyrsa Technologies’ minimally invasive SI joint fusion devices, enhancing market penetration, and providing advanced solutions for long-term pain relief in patients with chronic SI joint pain. Vyrsa Technologies is a US-based company that operates in the field of arthralgia, specifically focusing on chronic sacroiliac (SI) joint pain.

Regional Outlook

North America was the largest region in the arthralgia market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Arthralgia Market?

The arthralgia market consists of revenues earned by entities by providing services such as diagnosis services, treatment services, physical rehabilitation programs, and supportive services. The market value includes the value of related goods sold by the service provider or included within the service offering. The arthralgia market also includes sales of musculoskeletal diagnostic tools, biologic drugs, anti-inflammatory drugs, and regenerative therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Arthralgia Market Report 2026?

The arthralgia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the arthralgia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.